Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

P2950000

Primidone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-Desoxyphenobarbital, 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H14N2O2
Numéro CAS:
125-33-7
Poids moléculaire :
218.25
Numéro MDL:
MFCD00038662
Code UNSPSC :
41116107
ID de substance PubChem :
329820157
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

primidone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

Clé InChI

DQMZLTXERSFNPB-UHFFFAOYSA-N

Informations sur le gène

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Primidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1562000

Primidone, United States Pharmacopeia (USP) Reference Standard

1562033

Primidone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1562011

Primidone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP293

Primidone, British Pharmacopoeia (BP) Reference Standard

Y0002215

Primidone for system suitability, CRS European Pharmacopoeia (EP) Reference Standard

PHR3109

Primidone, pharmaceutical secondary standard, certified reference material

PHR3110

Primidone Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3111

Primidone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H351,H361d

Classification des risques

Acute Tox. 4 Oral - Carc. 2 - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

G J de Haan et al.
Nederlands tijdschrift voor geneeskunde, 147(47), 2325-2326 (2003-12-13)
The antiepileptic drug primidone is to be withdrawn from sale by January 2004. After this date, the drug will still be available for a time, but only on a limited basis. Most primidone users are elderly patients who have been
R Wilbur et al.
American journal of hospital pharmacy, 38(8), 1138-1143 (1981-08-01)
The evidence for the efficacy of anticonvulsant drugs in the control of seizures during alcohol withdrawal is examined. The literature on the use of anticonvulsants to control anxiety, irritability, tension, and other symptoms of abstinence syndrome is reviewed. The data
[Primidone].
K Furuno et al.
Nihon rinsho. Japanese journal of clinical medicine, 53 Su Pt 1, 928-930 (1995-02-01)
Sofia Markoula et al.
Therapeutic drug monitoring, 36(4), 494-498 (2014-02-25)
Lacosamide (LCM), a new antiepileptic drug (AED) approved as adjunctive therapy for the treatment of patients with partial-onset seizures, has limited pharmacokinetic and drug interaction data. The main objectives of the present study were to investigate the effects of dose
D Christidis et al.
Seizure, 15(1), 64-66 (2005-11-29)
Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major cause of death accounting for 7-17% of the mortality among epileptic patients. Prolongation of QT-interval has been issued as a major mechanism in SUDEP since it is associated with fatal cardiac
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique